Health / Nigeria

Sickle Cell is not rare — it is ignored (2)

Sickle Cell is not rare — it is ignored (2)

Last week, I argued that sickle cell disease is not simply a “rare” condition. For millions of families, particularly across Africa, it is an everyday reality.

The deeper problem is visibility. But visibility without action achieves very little. We can wear red. We can organise awareness events. We can post messages on social media. We can tell people what the letters SCD mean.

All of that has value. But after the banners come down and the social media posts disappear, what changes for the child experiencing another pain crisis? What changes for the mother who cannot afford treatment?

What changes for the adult afraid to tell an employer that they have sickle cell disease? And what changes for the patient sitting in severe pain, waiting to be believed? Awareness must eventually become action.

One of the greatest inequalities in sickle cell disease is the difference between what medicine can do and what patients can actually access. Modern medicine has transformed our understanding of SCD. There are established interventions that can reduce complications and improve outcomes, and advances in treatment continue.

But a medical breakthrough means little to a patient who cannot access it. This is particularly important for Africa. Nigeria has a substantial population living with SCD, yet many families must navigate healthcare costs alongside all the ordinary financial demands of life.

For families already struggling economically, chronic illness can become another financial emergency. Consultations cost money. Tests cost money. Medication costs money. Transport to hospital costs money.

Missing work to care for a sick child costs money. The economic burden of sickle cell disease therefore extends far beyond the hospital bill.

Living abroad has made me particularly conscious of this inequality. I have benefited from specialist sickle cell care. I know that when serious complications arise, there are specialists, investigations and treatment pathways available to me.

I am profoundly aware that my experience could have been very different had I lived somewhere where specialist care was unavailable or beyond my financial reach.

That knowledge stays with me. Nobody chooses the genes they inherit. So why should survival and quality of life depend so heavily on someone’s postcode, income or country of birth? We cannot discuss global sickle cell inequality without confronting that question.

There is another resource that healthcare systems too often undervalue: the patient. People who have lived with sickle cell disease for decades know their bodies.

They often recognise the beginning of a crisis. They know when pain feels different from their usual pain. They may know which interventions have helped previously, and which have not.

This knowledge should not replace clinical expertise, but neither should clinical expertise erase lived experience. The best healthcare is a partnership.

When a patient says, “Something isn’t right,” listening can matter enormously. Patient voices should also be present beyond the consultation room. People living with SCD should be involved in research priorities, healthcare policy, service design and public education. Do not simply study us; work with us.

Prevention and education also matter, particularly in countries where sickle cell is common. Knowing your genotype can help people make informed reproductive choices.

But genotype education must never become an excuse for stigma. People with sickle cell disease should never be made to feel that their lives are mistakes or that they are somehow responsible for having inherited a genetic condition.

Nor should couples be subjected to humiliation because of their genotype. Education should provide knowledge. Knowledge should create informed choice. And informed choice should be accompanied by compassion.

It would mean newborn screening reaching more babies. It would mean children receiving appropriate preventive and specialist care. It would mean healthcare workers being properly trained in SCD.

It would mean pain being treated promptly and compassionately. It would mean greater investment in research. It would mean psychological support being recognised as part of sickle cell care. It would mean families receiving clear information. It would mean workplaces understanding that chronic illness sometimes requires flexibility.

And it would mean ensuring that advances in sickle cell treatment do not become available only to people who are wealthy or fortunate enough to live in certain countries.

The future of sickle cell medicine cannot be discussed without Africa. The continent cannot merely be somewhere researchers collect data or recruit participants.

African clinicians, scientists, patients, advocates and communities must help shape the global research agenda. Nigeria, in particular, has an opportunity to become a major voice in sickle cell research, education and innovation.

Imagine what could happen if the scale of the challenge were matched by the scale of ambition. Imagine stronger screening programmes, better-equipped specialist centres, expanded research, greater public understanding and partnerships between Nigerian institutions and leading SCD centres internationally. The burden is enormous. But so is the potential.

Ultimately, this conversation is about more than sickle-shaped red blood cells. It is about whose suffering attracts attention. Whose illness attracts investment. Whose pain is believed. Whose life is considered worth improving.

For years, people living with sickle cell disease and their families have advocated, educated, fund raised and told their stories. We will continue. But responsibility cannot rest solely on patients.

Governments, healthcare systems, researchers, pharmaceutical companies, educators, employers and communities all have roles to play.

We have spent long enough asking people to become aware of sickle cell disease. Now we need to ask what they will do with that awareness. Because sickle cell is not rare. The people living with it are not invisible. And they should no longer have to shout to be seen.

If you would like to get in touch with me about Sickle cell, do so via my email address: [email protected].  And do check out my blog:     https://www.dailylivingwithsicklecell.com/    My book on Sickle Cell – HOW TO LIVE WITH SICKLE CELL and my other books are available for purchase on www.amazon.com.

Share this story WhatsApp Facebook X
Originally published by Punch
View on Punch

Comments 0

No comments yet. Start the conversation.

Loading the next story…